Market news

New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of...

Video webcast now available here SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech...

Daré’s proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposureCompany continues activities necessary to advance its Sildenafil Cream toward the...

Detailed price information for Dare Bioscience Inc (DARE-Q) from The Globe and Mail including charting and trades.

SAN DIEGO, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on clo...

--Daré Bioscience, Inc., a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that its President and Chief Executive Officer, Sabrina Martucci Johnson, has been named to the Forbes 2026" 50 Over 50: Innovation" list, recognizing women who are making...

Dare Bioscience transitions to a commercial-stage company with the launch of FloraSync LF5, while advancing its women's health pipeline and securing non-dilutive funding.

Moby summary of Daré Bioscience, Inc.'s Q2 2026 earnings call

SAN DIEGO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (Nasdaq: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that it has entered into a definitive securities purchase agreement with institutional investors for the purchase and sale of 4,379,581 shares of the Company’s common stock (or pre-funded warrants to purchase shares of common stock in lieu thereof), at a pr

Dare Bioscience (DARE) delivered earnings and revenue surprises of +39.39% and +1,775.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Company launches Flora Sync LF5™, the company's first directly commercialized product, began generating revenue in July DARE to PLAY™ Sildenafil Cream progressing toward national dispensing and initial revenue in the third quarter of 2026, with prescriptions and preorders already being accepted Building a commercial ecosystem to make it easier for women to discover, access and purchase products specifically designed for women Clinical pipeline continues to advance, led by positive interim Phase